PURPOSE: This Phase I, open-label, single-arm, dose-escalation study aimed to evaluate the safety and tolerability of the insulin-like growth factor (IGF-I/II) neutralizing antibody, MEDI-573, in Japanese patients with advanced solid tumours refractory to standard therapy or for which no standard therapy exists. The pharmacokinetics, pharmacodynamics and antitumour activity of MEDI-573 were also evaluated. METHODS: Three cohorts of patients received MEDI-573 in escalating order: cohort 1, 5 mg/kg on Day 1, 8 and 15; cohort 2, 15 mg/kg on Day 1, 8 and 15; cohort 3, 45 mg/kg on Day 1, of 21-day cycles. RESULTS: Ten patients who received at least one dose of MEDI-573 were evaluated. The median number of treatment cycles was 2.0 (range 1-6) and the median number of MEDI-573 doses received was 4.0 (range 1-17). The most commonly reported drug-related adverse events were fatigue (n = 2 patients), pyrexia (n = 2), diarrhoea (n = 2) and electrocardiogram QT prolongation (n = 2). No patients experienced a dose-limiting toxicity. Pharmacokinetics of MEDI-573 were linear with a dose-dependent increase. There were no complete or partial responses; four patients had an overall best response of stable disease. CONCLUSIONS: MEDI-573 is well tolerated at the doses investigated.
PURPOSE: This Phase I, open-label, single-arm, dose-escalation study aimed to evaluate the safety and tolerability of the insulin-like growth factor (IGF-I/II) neutralizing antibody, MEDI-573, in Japanese patients with advanced solid tumours refractory to standard therapy or for which no standard therapy exists. The pharmacokinetics, pharmacodynamics and antitumour activity of MEDI-573 were also evaluated. METHODS: Three cohorts of patients received MEDI-573 in escalating order: cohort 1, 5 mg/kg on Day 1, 8 and 15; cohort 2, 15 mg/kg on Day 1, 8 and 15; cohort 3, 45 mg/kg on Day 1, of 21-day cycles. RESULTS: Ten patients who received at least one dose of MEDI-573 were evaluated. The median number of treatment cycles was 2.0 (range 1-6) and the median number of MEDI-573 doses received was 4.0 (range 1-17). The most commonly reported drug-related adverse events were fatigue (n = 2 patients), pyrexia (n = 2), diarrhoea (n = 2) and electrocardiogram QT prolongation (n = 2). No patients experienced a dose-limiting toxicity. Pharmacokinetics of MEDI-573 were linear with a dose-dependent increase. There were no complete or partial responses; four patients had an overall best response of stable disease. CONCLUSIONS: MEDI-573 is well tolerated at the doses investigated.
Authors: Paul Haluska; Michael Menefee; Elizabeth R Plimack; Jonathan Rosenberg; Donald Northfelt; Theresa LaVallee; Li Shi; Xiang-Qing Yu; Patricia Burke; Jiaqi Huang; Jaiqi Huang; Jaye Viner; Jennifer McDevitt; Patricia LoRusso Journal: Clin Cancer Res Date: 2014-07-14 Impact factor: 12.531
Authors: Kai-Da Wu; Li Zhou; Douglas Burtrum; Dale L Ludwig; Malcolm A S Moore Journal: Cancer Immunol Immunother Date: 2006-07-11 Impact factor: 6.968
Authors: Jin Gao; Jon W Chesebrough; Susan A Cartlidge; Sally-Ann Ricketts; Leonard Incognito; Margaret Veldman-Jones; David C Blakey; Mohammad Tabrizi; Bahija Jallal; Pamela A Trail; Steven Coats; Klaus Bosslet; Yong S Chang Journal: Cancer Res Date: 2011-01-18 Impact factor: 12.701
Authors: Laura W Bowers; Emily L Rossi; Ciara H O'Flanagan; Linda A deGraffenried; Stephen D Hursting Journal: Front Endocrinol (Lausanne) Date: 2015-05-15 Impact factor: 5.555
Authors: Johann de Bono; Chia-Chi Lin; Li-Tzong Chen; Jesus Corral; Vasiliki Michalarea; Karim Rihawi; Michael Ong; Jih-Hsiang Lee; Chih-Hung Hsu; James Chih-Hsin Yang; Her-Shyong Shiah; Chia-Jui Yen; Alan Anthoney; Maria Jove; Susanne Buschke; René Fuertig; Ulrike Schmid; Rainer-Georg Goeldner; Natalja Strelkowa; Dennis Chin-Lun Huang; Thomas Bogenrieder; Chris Twelves; Ann-Lii Cheng Journal: Br J Cancer Date: 2020-03-12 Impact factor: 7.640